Integrating ADNI results into Alzheimer's disease drug development programs
- 31 August 2010
- journal article
- review article
- Published by Elsevier BV in Neurobiology of Aging
- Vol. 31 (8), 1481-1492
- https://doi.org/10.1016/j.neurobiolaging.2010.03.016
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCINeurobiology of Aging, 2009
- Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjectsNeuroImage, 2009
- Automatic quality assessment in structural brain magnetic resonance imagingMagnetic Resonance in Medicine, 2009
- Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNIHippocampus, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Predictors of progression of cognitive decline in Alzheimer’s disease: the role of vascular and sociodemographic factorsZeitschrift für Neurologie, 2009
- Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: Results from ADNI☆NeuroImage, 2008
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer DiseaseArchives of Neurology, 2008
- Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: An MRI study of 676 AD, MCI, and normal subjectsNeuroImage, 2008
- 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometryNeuroImage, 2008